Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05905003
Other study ID # 2020P002267
Secondary ID U24MH124629U01MH
Status Recruiting
Phase
First received
Last updated
Start date June 2, 2022
Est. completion date May 31, 2025

Study information

Verified date June 2023
Source Brigham and Women's Hospital
Contact Martha E Shenton, Ph.D.
Phone 617-699-6152
Email shenton@bwh.harvard.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) is a large international collaboration to develop algorithms using a set of clinical and cognitive assessments, multi-modal biomarkers, and clinical endpoints that can be used to predict the trajectories and outcomes of individuals at clinical high risk (CHR) for psychosis and to advance the testing of pharmacological interventions for CHR individuals in need. The goal is to accurately predict which individuals are likely to remit, experience an acute psychotic episode, or have intermediate outcomes that feature persistent attenuated psychotic and/or mood symptoms along with functional impairment. The prediction algorithms will have the potential to serve as early indicators of treatment efficacy in CHR persons. The AMP SCZ research program is made up of the Psychosis Risk Evaluation, Data Integration, and Computational Technologies - Data Processing, Analysis and Coordination Center (PREDICT-DPACC) and two clinical research networks, the Psychosis-Risk Outcomes Network (ProNET) and the Trajectories and Predictors in the Clinical High Risk for Psychosis Population: Prediction Scientific Global Consortium (PRESCIENT) networks. The two clinical research networks will recruit a large cohort of CHR young people aged 12-30 years (n=1,977) and healthy control (HC) participants (n=640) across 42 participating investigative sites from 13 countries. CHR participants will complete screening, baseline assessments and a battery of follow-up assessments across 18 - 24 months. HC participants will complete screening and baseline assessments and a subset (5 per site) will complete month 2, 12 and 24 visits.


Description:

The Accelerating Medicines Partnership (AMP®) is a public-private partnership between the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), the European Medicines Agency, and multiple public and private organizations. The goal of the AMP Schizophrenia (AMP SCZ) program, a multi-continent consortium, is to develop a deep biomarker-informed functional characterization and longitudinal clinical profiling of study participants at clinical high risk (CHR) for psychosis. The data will support the development of algorithms of clinical and biological measures to predict the trajectories and outcomes of CHR individuals to identify enriched CHR patient populations to enable proof of principle intervention studies for early intervention in schizophrenia. These tools will allow the assessment of biomarkers and outcome measures as early indicators of pharmacologic treatment efficacy. See the AMP SCZ website link for a detailed description of study goals (https://www.ampscz.org/about/goals/). The Accelerating Medicines Partnership® Schizophrenia Observational Study: Psychosis Risk Evaluation, Data Integration, and Computational Technologies Data Processing, Analysis and Coordination Center (AMP SCZ® Observational Study: PREDICT-DPACC) based out of Brigham and Women's Hospital (BWH) and Mass General Brigham (MGB) is one of three research projects supported by the AMP SCZ program. The AMP SCZ Observational Study: PREDICT-DPACC works with two Clinical High Risk (CHR) research networks (described below) to meet the following goals: - Capture data from the research networks in a uniform manner. - Build flexible infrastructure to accommodate multiple data types. - Develop and refine pipelines that provide rapid data processing (in close to real-time) and quality assurance (QA) and quality control (QC). - Provide data coordination, management, and monitoring of data. - Develop powerful and robust stratification tools to identify & validate biomarkers and predict individual outcome trajectories. - Assist in archiving data and making it publicly available in the NIMH Data Archive (NDA). Please see (https://nda.nih.gov/ampscz/). - Disseminate information, including tools developed, to the general research community, and provide outreach to the community via a website. MGB institutions do not provide or enroll participants for this study but serve as the AMP SCZ DPACC for two CHR Research Networks (RNs) where consent and all clinical testing and data collection occur. MGB is a data recipient only, not a data provider. The Mass General Brigham IRB is the IRB of record for the AMP SCZ® Observational Study: PREDICT-DPACC and the IRB status is exempt. The two CHR research networks (RNs) that also make up the AMP SCZ program are: The Psychosis-Risk Outcomes Network (ProNET) is based out of Yale University, which serves as the hub for this network and consists of a network of sites in the US, Canada, Europe, and Asia. Northwell Health is the IRB of record for all US sites in the ProNET RN. All foreign ProNET sites submit to their local IRBs. The Trajectories and Predictors in the Clinical High Risk for Psychosis Population: Prediction Scientific Global Consortium (PRESCIENT), is based out of the Center for Youth Mental Health at the University of Melbourne and at Orygen, Melbourne, Australia, which serves as the hub for this network, and consists of a network of sites in Australia, Europe, and Asia. The Melbourne Health Research Governance and Ethics Office for Research is the IRB of record for all Australian sites in the PRESCIENT research network. European and Asian sites submit to their local IRBs. Acquisition Sites collect the data and transfer it directly to Brigham and Women's Hospital, which is the main site for the Data Processing Analysis and Coordination Center (DPACC). See the AMP SCZ website for a searchable map with contact information for all study sites (https://www.ampscz.org/about/map/). Please also see the AMP SCZ website for additional information about the ProNET and PRESCIENT research networks and the PREDICT-DPACC coordination center (https://www.ampscz.org/about/networks-coordination/). This is a non-interventional study examining clinical trajectories and predictors of outcomes in the CHR population. The CHR cohort and HCs will be assessed with a core set of measures at baseline and 2 months post-baseline, with additional assessments completed at other time points. CHR subjects will be assessed longitudinally for 2 years. Participants who develop first-episode psychosis ('converted' cases) during their study participation will continue to be assessed as scheduled. Measures include clinical, cognitive, neurophysiology, neuroimaging, genetics and fluid biomarkers, speech and facial expression (audio/video recordings are optional), and outcome assessments. Digital assessments such as daily ecological momentary assessment (daily digital diary entries) and passive sensing measurements (actigraphy and geolocation) are optional. See the AMP SCZ website for detailed descriptions of the study design (https://www.ampscz.org/scientists/design/) and protocol (https://www.ampscz.org/wp-content/uploads/2023/01/AMP-SCZ-Protocol-Summary-for-Distribution_ 24JAN2023.pdf).


Recruitment information / eligibility

Status Recruiting
Enrollment 2617
Est. completion date May 31, 2025
Est. primary completion date December 31, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 12 Years to 30 Years
Eligibility Inclusion Criteria: - Individuals between 12 and 30 years old; - Understand and sign an informed consent (or assent for minors) document; - Meet diagnostic criteria for CHR from the Positive SYmptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPS (PSYCHS). Exclusion Criteria: - Antipsychotic medication exposure equivalent to a total lifetime haloperidol dose of >50 mg or current antipsychotic medication at time of screening assessment; - Documented history of intellectual disability; - Past or current clinically relevant central nervous system disorder; - Traumatic brain injury that is rated as 7 or above on the Traumatic Brain Injury screening instrument; - Current or past treated or untreated psychotic episode, as determined using the PSYCHS. See also the AMP SCZ website link for a description of eligibility criteria (https://www.ampscz.org/participate/eligible/).

Study Design


Locations

Country Name City State
Australia HEP and co-located Headspace Adelaide Adelaide South Australia
Australia Headspace, Craigieburn Craigieburn Victoria
Australia Headspace, Glenroy Glenroy Victoria
Australia Headspace Melton Melton South Victoria
Australia Orygen Specialist Programs, Melbourne Parkville Victoria
Australia Headspace, Sunshine Sunshine Victoria
Australia Headspace, Werribee Werribee Victoria
Canada University of Calgary Calgary Alberta
Canada McGill University Montréal Quebec
Chile Hospital Clínico Universidad de Chile (HCUCH) Santiago Región Metropolitana
China Shanghai Jiao Tong University Shanghai
Denmark Copenhagen Research Center for Mental Health (CORE) Copenhagen
Germany Klinik für Psychiatrie und Psychotherapie, University of Cologne Cologne Brescia
Germany The University Hospital Jena, Department of Psychiatry Jena Thuringia
Germany Ludwig-Maximilians-Universität Munich Munich
Hong Kong The University of Hong Kong, Department of Psychiatry Hong Kong
Italy University of Pavia Pavia
Korea, Republic of Department of Psychiatry, Chonnam National University Hospital & Mindlink Gwangju
Korea, Republic of Seoul National University College of Medicine Seoul
Singapore Early Psychosis Intervention Programme (EPIP) Clinic, Institute of Mental Health Singapore
Spain Instituto de Psiquiatría y Salud Mental Hospital General Universitario Gregorio Marañón Madrid
Switzerland Treatment and Early Intervention in Psychosis Program (TIPP) & Center for Psychiatric Neuroscience (CNP), Department of Psychiatry, Lausanne University Hospital Lausanne
United Kingdom Forward Thinking Birmingham Birmingham
United Kingdom University of Cambridge Cambridge
United Kingdom King's College London London
United States University of Georgia Athens Georgia
United States Beth Israel Deaconess Medical Center Boston Massachusetts
United States University of North Carolina at Chapel Hill Chapel Hill North Carolina
United States University of Oregon Eugene Oregon
United States Northwestern University Evanston Illinois
United States Hartford Healthcare Hartford Connecticut
United States University of California Irvine Irvine California
United States University of California Los Angeles Los Angeles California
United States Yale University/Connecticut Mental Health Center New Haven Connecticut
United States Icahn School of Medicine at Mount Sinai New York New York
United States Temple University Philadelphia Pennsylvania
United States University of Pennsylvania Philadelphia Pennsylvania
United States University of Pittsburgh Pittsburgh Pennsylvania
United States Northwell Health Queens New York
United States Washington University Saint Louis Missouri
United States University of California San Diego San Diego California
United States University of California San Francisco San Francisco California

Sponsors (4)

Lead Sponsor Collaborator
Brigham and Women's Hospital National Institute of Mental Health (NIMH), Orygen, Yale University

Countries where clinical trial is conducted

United States,  Australia,  Canada,  Chile,  China,  Denmark,  Germany,  Hong Kong,  Italy,  Korea, Republic of,  Singapore,  Spain,  Switzerland,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Conversion to Psychosis Conversion to psychosis as defined by psychosis threshold criteria on the PSYCHS. By 24 month follow-up.
Secondary Remission Recovery from CHR as defined by PSYCHS criteria. By 24 month follow-up.
Secondary Non-conversion/Non-remission Continued CHR condition as defined by PSYCHS criteria. By 24 month follow-up.
See also
  Status Clinical Trial Phase
Recruiting NCT04929938 - Application of UP for Transdiagnostic Treatment of Emotional Disorders for UHR for Psychosis Patients N/A
Recruiting NCT05863572 - Strengthening Care in Collaboration With People With Lived Experience of Psychosis in Uganda N/A
Completed NCT04277585 - Improving Access to Early Psychosis Coordinated Specialty Care N/A
Recruiting NCT06197048 - Effect of Nutritional Counseling on Anthropometry and Biomarkers in Patients Diagnosed With Schizophrenia/Psychosis or Bipolar Affective Disorder N/A
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Terminated NCT04404712 - FAAH Availability in Psychiatric Disorders: A PET Study Early Phase 1
Recruiting NCT05769933 - Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
Recruiting NCT04298450 - ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention N/A
Not yet recruiting NCT05558332 - Youth Nominated Support Team N/A
Not yet recruiting NCT05358457 - Pilot Study to Evaluate the Effectiveness of Online Familiar Metacognitive Training (MCTf) N/A
Not yet recruiting NCT03807388 - ReMindCare App for Patients From First Episode of Psychosis Unit. N/A
Completed NCT02895269 - COllaborative Shared Care to IMprove Psychosis Outcome N/A
Recruiting NCT02622048 - Understanding and Helping Families: Parents With Psychosis N/A
Completed NCT02733575 - Compassion Focused Therapy for Distressing Experiences N/A
Completed NCT02531243 - Computer-Aided Learning for Managing Stress N/A
Completed NCT02653729 - Cbt for Psychosis and Affect on Psychosis Symptoms Phase 2
Not yet recruiting NCT02244970 - Mindfulness RCT for Early Psychosis N/A
Enrolling by invitation NCT01364818 - Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment N/A
Withdrawn NCT00786318 - Ziprasidone vs Standard Therapy for Agitated Patients in the ED Phase 4
Recruiting NCT00722163 - A Randomized Controlled Trial of Individual Therapy for First Episode Psychosis Phase 0